Global Biologics Market, by Product Type (Monoclonal Antibodies, Vaccines, Recombinant Proteins, Cell Therapy, Gene Therapy), by Application (Oncology, Immunology, Auto-Immune Diseases, Infectious Diseases), by Source Material (Human, Bacteria, Yeast) - Global Industry Insights, Trends and Forecast (2017-2025)

Created On: Aug-2018
Report ID: IR158
Format: PDF

Biologics are drugs that are prepared from the cells, genes, tissues, recombinant proteins, and other biological components extracted from living organisms which include human, microbes and animals.

The Global Biologics Market is anticipated to grow at a faster pace in the forecast period owing to its rising demand in treatment of a multiple diseases such as cancer, cardio-vascular diseases, hepatitis B and others. The increase in incidence of chronic diseases such as cancer and various metabolic disorders such as diabetes mellitus, Gaucher’s disease, etc. has led to the escalation of several biomedical research activities for the manufacture of biologics, which motivated giant healthcare companies to invest in this market. According to a study, nearly 800 biological molecules are in development phase, which can be further used for the manufacture of biologics. Moreover, initiatives taken by governing bodies of several countries to improve people’s health and provide better medical facilities are resulting in the escalation of regulatory approval of new drugs based on biologics. In the last decade one-third of the total drugs approved were biologics. This will further help the market to grow over the forecast years. The demand for biological drugs over chemically synthesized drugs is also anticipated to generate higher revenue over the coming years, and this will significantly drive the market.

Global biologics market is majorly restrained by the high manufacturing costs, coupled with the complexity in their manufacturing process due to their extra-sensitivity towards environmental factors like heat, light, moisture, etc. The commercialization of non-generic biosimilars will act as an additional restraint to the growth of biologics market over the projected period.

Monoclonal antibodies and their derivatives are of great importance for pharmaceutical companies, as they find a wide-range of applications in the production of biologics because of their favorable properties. The monoclonal antibodies segment is predicted to lead the biologics market over the forecast period, primarily attributed by the increasing product demand for personalized therapies. Moreover, extensive research activities in the development of antibodies to discover various targeted therapies for a wide-range of diseases, like cancers, infections, and multiple immunological disorders.

The biologics market for oncology and auto-immune diseases is predicted to have the dominant share over the forecast period. Many small-sized and mid-sized companies are highly focusing on oncology and immunology segments, as they have high unmet medical needs, and they require higher acceptability. This primarily attributes to the growth of biologics market for oncology and auto-immune diseases segments.

North America is expected to hold the largest share in the global biologics market during the forecast period. Europe and Asia Pacific are anticipated to follow North America in terms of market size. The arrival of new healthcare technologies and advancement in biomedical engineering has escalated the growth of the market in the North America region, particularly in the U.S. Chronic diseases such as cancer and auto-immune diseases are in high prevalence in this region, according to NIH. As the biologics are majorly used for the treatment of these diseases, the biologics market is predicted to have the highest share in this region. This is further attributed by the presence of large number of market players, which has further helped the growth of biologics sales in this region.

Key market players operating in biologics market include Becton Dickinson & Company, Retractable Technologies, Inc., Bayer AG, Unilife Corporation, Smiths Medicals, Roche Diagnostics, Terumo Corporation, Novartis AG, AstraZeneca and Lundbeck.

Our Research Approach Includes
  •  Market Outlining
  •  Framing discussion guide
  •  Data Validation
  • Data Analysis
  •  Re-Validation and Finalization of Data
  •  Report Insights and Publishing
Our Research Approach Includes
  •  Market Outlining
  •  Framing discussion guide
  •  Data Validation
  • Data Analysis
  •  Re-Validation and Finalization of Data
  •  Report Insights and Publishing
Reach Out to us